Product Description
A hormone made from testosterone in the prostate, testes, and certain other tissues. It is needed to develop and maintain male sex characteristics, such as facial hair, deep voice, and muscle growth. High amounts of androstanolone may increase the growth of prostate cancer and make it harder to treat. Also called DHT and dihydrotestosterone. (Sourced from: https://www.cancer.gov/publications/dictionaries/cancer-terms/def/androstanolone)
Mechanisms of Action: AR Agonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Transdermal,Topical
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: France | India | Slovenia | Taiwan | United Kingdom
Approved Indications: None
Known Adverse Events: None
Company: Ascend
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 2: Hypothalamic Diseases|Hypothalamic Cancer|Anal Cancer|Prostatic Hyperplasia|Vascular Cancer|Hypogonadism|Prostate Cancer|Breast Cancer|Testicular Diseases|Skin Diseases, Vascular|Testicular Cancer|Bladder Cancer|Inflammation|Protein Deficiency|Bone Cancer|Deficiency Diseases|Prostatic Diseases|Pituitary Diseases|Pituitary Cancer|Pregnancy Outcomes|Hypopituitarism|Skin Cancer
Phase 1: Prostate Cancer
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| FDHT - version 1, 9 March 2015 | P2 |
Terminated |
Prostate Cancer |
2018-09-15 |
|
| [18F]FDHT PET in hormone naive prostate cancer | P2 |
Active, not recruiting |
Bone Cancer|Prostate Cancer |
2016-02-11 |
|
| 2012-003981-42 | P2 |
Completed |
Breast Cancer |
2015-05-13 |
|
| IRB00015971 | P1 |
Terminated |
Prostate Cancer |
2013-03-01 |